Creo Medical Group (LON:CREO) Stock Price Down 9.5% – Time to Sell?

Creo Medical Group PLC (LON:CREO)’s stock price traded down 9.5% during trading on Monday . The company traded as low as GBX 17 ($0.21) and last traded at GBX 17.20 ($0.22). 1,215,246 shares traded hands during trading, an increase of 67% from the average session volume of 726,307 shares. The stock had previously closed at GBX 19 ($0.24).

Creo Medical Group Stock Down 4.8 %

The stock’s fifty day moving average is GBX 18.53 and its 200 day moving average is GBX 21.62. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96. The company has a market capitalization of £64.48 million, a P/E ratio of -2.52 and a beta of 0.86.

Insider Activity at Creo Medical Group

In related news, insider Kevin Crofton acquired 1,179,000 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of GBX 17 ($0.21) per share, for a total transaction of £200,430 ($252,844.71). Also, insider Richard John Rees purchased 4,712 shares of the firm’s stock in a transaction that occurred on Thursday, January 16th. The stock was acquired at an average price of GBX 19 ($0.24) per share, with a total value of £895.28 ($1,129.41). Insiders bought 1,188,424 shares of company stock worth $20,222,056 in the last three months. 22.43% of the stock is owned by insiders.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.